$19.61
1.24% today
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US86366E1064
Symbol
GPCR

Structure Therapeutics Stock price

$19.61
+1.42 7.81% 1M
-1.42 6.75% 6M
-7.51 27.69% YTD
-19.54 49.91% 1Y
+4.61 30.73% 3Y
+4.61 30.73% 5Y
+4.61 30.73% 10Y
+4.61 30.73% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.24 1.24%
ISIN
US86366E1064
Symbol
GPCR
Industry

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$282.2m
Net debt
positive
Cash
$786.5m
Shares outstanding
172.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
95.7%
Return on Equity
-14.2%
ROCE
-28.3%
ROIC
-1,116.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-218.6m | $-238.0m
EBIT
$-219.7m | $-192.9m
Net Income
$-179.0m | $-185.5m
Free Cash Flow
$-164.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-79.3% | -51.4%
EBIT
-79.4% | -21.9%
Net Income
-78.2% | -51.4%
Free Cash Flow
-55.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.0
FCF per Share
$-1.0
Short interest
18.0%
Employees
199
Rev per Employee
$0.0
Show more

Is Structure Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Structure Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Structure Therapeutics forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Structure Therapeutics forecast:

Buy
95%
Hold
5%

Financial data from Structure Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 56 56
33% 33%
-
- Research and Development Expense 164 164
104% 104%
-
-219 -219
79% 79%
-
- Depreciation and Amortization 1.10 1.10
80% 80%
-
EBIT (Operating Income) EBIT -220 -220
79% 79%
-
Net Profit -179 -179
78% 78%
-

In millions USD.

Don't miss a Thing! We will send you all news about Structure Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Structure Therapeutics Stock News

Neutral
GlobeNewsWire
16 days ago
Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts
Neutral
GlobeNewsWire
2 months ago
SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.
Positive
Seeking Alpha
5 months ago
Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development field, Structure's oral small mo...

Company Profile

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in San Francisco, CA.

Head office Cayman Islands
CEO Raymond Stevens
Employees 199
Founded 2019
Website structuretx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today